AA
Alain P. Algazi
Highly rated in
24
conditions
Highly rated in
24
conditions
Check Dr. Alain P. Algazi's experience treating your condition:
About Dr. Alain P. Algazi

Alain Algazi is a Hematologist Oncology expert in San Francisco, California. Algazi has been practicing medicine for over 18 years and is highly rated in 24 conditions, according to our data. His top areas of expertise are Melanoma, Head and Neck Squamous Cell Carcinoma (HNSCC), Polymorphous Low Grade Adenocarcinoma, and Nasopharyngeal Carcinoma. He is licensed to treat patients in California.

His clinical research consists of co-authoring 65 peer reviewed articles and participating in 11 clinical trials in the past 15 years.

Insurance

MediFind strives to display the most accurate insurance information for every doctor. If you do not see your insurance listed for Dr. Alain P. Algazi it is best to call his office and ask if your insurance is accepted.

Accepts Medicare

Call to see if your plan is accepted.
Locations
1600 Divisadero St, 3rd Floor, San Francisco, CA 94115
Other Locations
1825 Fourth St., Fifth Floor, San Francisco, CA 94158
Background & Education
Graduate Institution
University Of California, Geffen School Of Medicine, 2004
Specialties
Hematology Oncology
Licenses
Internal Medicine in CA
Hospital Affiliations
UCSF Helen Diller Medical Center At Parnassus Heights
San Francisco Medical Center
UCSF Medical Center At Mount Zion
Chinese Hospital
Languages Spoken
English
Gender
Male
Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Doctors who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.


8 Clinical Trials

A Phase II Study of Preoperative Immunotherapy in Patients With Squamous Cell Carcinoma of the Head and Neck
Expanded Access for the Treatment of Cancers With Rearranged During Transfection (RET) Activation
A Multi-Center, Phase II, Open Label, Single-Arm Trial of Durvalumab and Epacadostat in Patients With Unresectable, Recurrent, and Metastatic EBV+ NPC
A Phase 1b Study of Intratumoral IMO-2125 in Patients With Refractory Solid Tumors (ILLUMINATE-101)
A Randomized Phase II Trial of Intermittent Versus Continuous Dosing of Dabrafenib (NSC-763760) and Trametinib (NSC-763093) in BRAF V600E/K Mutant Melanoma
View 7 Less Clinical Trials -

Save this doctor for later
Sign Up
Looking for the best doctor for you?
Start Here
Is this your doctor?
Find a second opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn more
Similar Doctors